Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022

Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022

$20.00 USD
$20.00 USD
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022

Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022

$20.00
$20.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

  • Share positive thoughts and feedback from your customer.

    Author

  • Share positive thoughts and feedback from your customer.

    Author

  • Share positive thoughts and feedback from your customer.

    Author
    View full details

    Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022

    Penn Medicine CV Pharmacologic Risk Reduction
    Include: 13 videos + 16 pdfs, size: 3.02 GB
    Date & Location

    Friday, September 30, 2022, 7:45 AM – 2:00 PM, Virtual, Philadelphia, PA

    Course Overview

    CVD is the leading cause of death in the US. Hypertension and diabetes are among the foremost risk factors for the development of CVD, stroke, peripheral artery disease, and heart attack. This program will provide an overview of recent advances that target the underlying pathophysiology of cardiovascular disease. The focus of the program will be on the new guidelines for hypertension, DM and CKD and will discuss the advances in pharmacotherapeutics in these fields.

    Target Audience
    Penn Medicine CV Pharmacologic Risk Reduction
    Specialties – FAMILY MEDICINE, FAMILY MEDICINE – Geriatric Medicine, INTERNAL MEDICINE, INTERNAL MEDICINE – Advanced Heart Failure and Transplant Cardiology, INTERNAL MEDICINE – Clinical Cardiac Electrophysiology, INTERNAL MEDICINE – Endocrinology, Diabetes and Metabolism, INTERNAL MEDICINE – Geriatric Medicine, INTERNAL MEDICINE – Interventional Cardiology, INTERNAL MEDICINE – Nephrology, INTERNAL MEDICINE – Sports Medicine, OBSTETRICS AND GYNECOLOGY, OBSTETRICS AND GYNECOLOGY – Maternal and Fetal Medicine, PREVENTIVE MEDICINE – Clinical Informatics, PUBLIC HEALTH AND GENERAL PREVENTIVE MEDICINE
    Learning Objectives

    After completing this activity, participants should be able to:

    1. Select appropriate medications to reduce adverse cardiovascular outcomes in high-risk and vulnerable populations
    2. Identify appropriate blood pressure goals and management in several special patient populations
    3. Review the controversies regarding the appropriate treatment of and management of pregnant patients at risk for CVD.
    4. Achieve competence in providing the best screening and treatment options for hypertension in patients with hyperlipidemia in young patients.
    5. Apply appropriate pharmacologic and non-pharmacologic approaches to cardiovascular risk prevention

     

     Topics:

    • BP Goals and Use of Thiazides in Advanced CKD.mp4
      BP Goals and Use of Thiazides in Advanced CKD.pdf
      BP Goals Management in Elderly (STEP Trial and SPRINT).mp4
      BP Goals Management in Elderly (STEP Trial and SPRINT).pdf
      BP22_Brochure_v4.pdf
      Cholesterol.mp4
      Cholesterol.pdf
      Clinical Case Discussion FOUNDATIONS- REFRESHER OF THE CURRENT GUIDELINES.pdf
      Clinical Case Discussion SPECIAL POPULATIONS.pdf
      DM Weight loss.mp4
      DM Weight loss.pdf
      Hypertension.mp4
      Hypertension.pdf
      Lipid Management and Risk Assessment in Younger Patients.mp4
      Lipid Management and Risk Assessment in Younger Patients.pdf
      New Agents in Lipid Management.mp4
      New Agents in Lipid Management.pdf
      Non-steroidal MRAs in HTN, DM2, and CKD.mp4
      Non-steroidal MRAs in HTN, DM2, and CKD.pdf
      Peripartum CV Risk Reduction.mp4
      Peripartum CV Risk Reduction.pdf
      Polypill – Quad Study Combo Therapy for BP and Lipids.mp4
      Polypill – Quad Study Combo Therapy for BP and Lipids.pdf
      Population-Wide Effects and Local Public Health Efforts of Sodium Reduction.mp4
      Population-Wide Effects and Local Public Health Efforts of Sodium Reduction.pdf
      Update in Renal Denervation.mp4
      Update in Renal Denervation.pdf
      Weight Loss Strategies in Highly Comorbid Patients.mp4
      Weight Loss Strategies in Highly Comorbid Patients.pdf